Intravenous and Subcutaneous Vedolizumab for Moderately to Severely Active Ulcerative Colitis in Iran: A Model-Based Cost-Effectiveness Evaluation Publisher



Niksalehi K^{1, 2} ; Oyarhossein A² ; Fariman S³ ; Ahmadi A⁴ ; Azadmehr B⁵ ; Karimpourfard N² ; Vaziri L⁶ ; Afzali M¹
Source: Expert Review of Pharmacoeconomics and Outcomes Research Published:2025

Abstract

Objective: To evaluate the cost-effectiveness of intravenous and subcutaneous vedolizumab compared to infliximab for moderately to severely active ulcerative colitis (UC) from an Iranian societal perspective. Methods: A decision-analytic cost-utility model was developed using a decision tree and a Markov model. Direct and indirect costs were calculated. Treatment effectiveness and health state utility values were extracted from published literature. Effects were estimated using quality-adjusted life-years (QALYs). Costs and QALYs were projected over a lifetime and discounted at 3% per year. Deterministic and probabilistic sensitivity analyses were performed to evaluate uncertainties. Results: In base-case analysis, infliximab was associated with $28,888.5 costs and 15.17 QALYs. Vedolizumab was associated with 15.34 QALYs and costs of $27,916.90 for IV (induction and maintenance) and $28,200.40 for IV (induction) followed by SC (maintenance). The ICERs were estimated at -$5673.3/QALY and -$4,017.8/QALY, remaining negative across all sensitivity analyses. The cost of infliximab and vedolizumab and the probability of response to vedolizumab during maintenance were the key determinants of cost-effectiveness. Conclusions: Vedolizumab (both IV and SC) resulted in reduced costs and improved QALYs compared to infliximab for moderate to severe UC in Iran. Therefore, we recommended including vedolizumab in the Iranian national formulary as a cost-effective treatment strategy. © 2025 Informa UK Limited, trading as Taylor & Francis Group.